The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...

WAYNE, Pa., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the results of four studies that were accepted at the ICS 2020 Annual Meeting – Online reinforcing the ...

Both Rezūm® and Urolift® are relatively new treatments for BPH, as countries begin reimbursing for these treatments, the market will grow significantly.” — Dr. Kamran Zamanian, Senior Partner and CEO ...

Pooled outcomes in more than 330 UroLift ® System subjects treated in a controlled setting were analyzed and reported by Claus Roehrborn et. al. PUL with the UroLift ® System was durable in most ...

Teleflex Incorporated TFX recently unveiled the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System together with real-world data presentations at the American Urological Association ...

More than 50% of men over the age of 50 suffer from benign prostatic hyperplasia, also known as an enlarged prostate. While BPH is common for older men, causing the frequent urge to urinate — ...

PLEASANTON, Calif., March 9, 2020 /PRNewswire-PRWeb/ -- NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today ...

NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...